You're signed outSign in or to get full access.
MWG Management LTD.
MWG Management Ltd. is an investment management firm registered with the SEC, filing under CIK 0001845151. The firm appears to primarily manage a concentrated portfolio of publicly-traded equities, as reported in regular 13F filings since 2021. Limited public information is available about its founding year, headquarters location, or employee count. MWG Management Ltd.'s disclosed regulatory assets under management as of the June 2025 13F-HR filing is $52 million. The firm serves institutional investors by managing a small pool of concentrated equity positions.
Investment Strategy
MWG Management Ltd. operates a concentrated equity strategy, holding a few high-conviction positions in publicly traded companies primarily in the biotechnology sector. Its 13F filings show significant allocations to companies such as Beam Therapeutics, Lyell Immunopharma, and Prime Medicine, with portfolio activity suggesting an active approach, including substantial net sales in recent quarters. The fund's focus appears to be on growth- and innovation-driven equities within healthcare and related fields.
Latest 13F Filing Activity
MWG Management LTD. filed their most recent 13F report on Jun 30, 2025 disclosing 3 equity positions with a total 13F market value of $52M. The fund increased holdings in Prime Medicine Inc., Lyell Immunopharma Inc., Beam Therapeutics Inc.. MWG Management LTD. reduced exposure to Beam Therapeutics Inc., Lyell Immunopharma Inc., Prime Medicine Inc..
Top Holdings
Equity Positions (3)
Industry Allocation
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more